HOME ·

09969.HK

INNOCARE (09969.HK): Lilly Licensing Deal Worth Up to US$3.25B
Tags：
INNOCARE09969.HKstrategic cooperation
2026-09-24
INNOCARE (09969.HK): Phase III Trial of Fadeucravacitinib (ICP-488) for Moderate to Severe Plaque Psoriasis Meets Primary Endpoint
Tags：
INNOCARE09969.HKClinical Trialprimary endpoint
2026-07-27
INNOCARE (09969.HK): TYK2 Inhibitor Soficitinib (ICP-332) Meets Primary Endpoint in Phase II for Non-Segmental Vitiligo, 24-Week F-VASI Reduced by Around 39%-41% vs Baseline
Tags：
INNOCARE09969.HKClinical Trial
2026-07-16
InnoCare Pharma Limited(09969.HK): Phase III Registrational Trial of Soficitinib (ICP-332) for Moderate-to-Severe Atopic Dermatitis Meets Primary Endpoint Successfully
Tags：
InnoCare Pharma Limited09969.HK
2026-07-15
INNOCARE(09969.HK): NDA of Orelabrutinib for ITP Accepted by NMPA
Tags：
INNOCARE09969.HKNew Drug Marketing Application
2026-05-28
INNOCARE(09969.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 105.82 million, YoY increase of 488.93%
Tags：
INNOCARE09969.HKfinancials
2026-04-24